G1 THERAPEUTICS (GTHX) Now Covered by Analysts at BTIG Research

BTIG Research assumed coverage on shares of G1 THERAPEUTICS (NASDAQ:GTHX) in a research report sent to investors on Tuesday morning. The firm issued a buy rating and a $38.00 price target on the stock.

Other equities research analysts have also issued reports about the company. Zacks Investment Research lowered G1 THERAPEUTICS from a hold rating to a sell rating in a research report on Wednesday, October 11th. Cowen reissued a buy rating on shares of G1 THERAPEUTICS in a research report on Wednesday, November 8th. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. G1 THERAPEUTICS has an average rating of Buy and a consensus price target of $31.40.

G1 THERAPEUTICS (NASDAQ:GTHX) traded down $1.22 during trading on Tuesday, hitting $19.25. The stock had a trading volume of 144,000 shares, compared to its average volume of 112,090. G1 THERAPEUTICS has a 12 month low of $12.04 and a 12 month high of $28.67.

In other G1 THERAPEUTICS news, Director Fredric N. Eshelman purchased 250,000 shares of the stock in a transaction dated Monday, November 13th. The shares were bought at an average cost of $19.73 per share, with a total value of $4,932,500.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Medimmune Ventures, Inc. sold 200,000 shares of the firm’s stock in a transaction on Monday, November 20th. The shares were sold at an average price of $20.01, for a total value of $4,002,000.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 533,906 shares of company stock worth $10,596,644.

Several institutional investors and hedge funds have recently modified their holdings of the company. Alps Advisors Inc. increased its holdings in shares of G1 THERAPEUTICS by 9.1% during the third quarter. Alps Advisors Inc. now owns 27,766 shares of the company’s stock valued at $691,000 after purchasing an additional 2,317 shares during the period. Chartwell Investment Partners LLC increased its holdings in shares of G1 THERAPEUTICS by 5.0% during the third quarter. Chartwell Investment Partners LLC now owns 92,558 shares of the company’s stock valued at $2,303,000 after purchasing an additional 4,388 shares during the period. American International Group Inc. acquired a new position in shares of G1 THERAPEUTICS during the third quarter valued at $130,000. California State Teachers Retirement System acquired a new position in shares of G1 THERAPEUTICS during the third quarter valued at $319,000. Finally, Schwab Charles Investment Management Inc. acquired a new position in shares of G1 THERAPEUTICS during the third quarter valued at $364,000. 43.25% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “G1 THERAPEUTICS (GTHX) Now Covered by Analysts at BTIG Research” was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The original version of this piece can be read at https://sportsperspectives.com/2017/12/20/g1-therapeutics-gthx-now-covered-by-analysts-at-btig-research.html.

G1 THERAPEUTICS Company Profile

G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.

Analyst Recommendations for G1 THERAPEUTICS (NASDAQ:GTHX)

Receive News & Ratings for G1 THERAPEUTICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 THERAPEUTICS and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply